Somerset, NJ – September 23, 2011 — Dr. Hector F. DeLuca, Professor Emeritus, Department of Biochemistry, University of Wisconsin-Madison, and Julien Meissonnier, Director of Research & Development, Catalent Pharma Solutions will discuss the current and future of oral vitamin D3 analogs; main biopharmaceutical, physico-chemical and industrial hurdles to the development of appropriate drug delivery systems; and the preferred drug delivery systems for vitamin D3 analogs at a complimentary webinar on Tuesday, September 27th from 10:00 to 11:30 am EDT.
Dr. Hector DeLuca earned a BA in chemistry (with honors) from the University of Colorado in 1951, and a Ph.D. in biochemistry from the University of Wisconsin-Madison in 1955 with Dr. Harry Steenbock, a pioneer in vitamin D research. In 1959, Dr. DeLuca joined the Biochemistry Department at the University of Wisconsin as an Assistant Professor, and later was promoted to full Professorship. In June 2011 he became Professor Emeritus of Biochemistry. Dr. DeLuca has received numerous local and international awards and honors. He was elected to the membership of the U.S. National Academy of Sciences and the American Academy of Sciences in 1979. He is a member of a number of scientific societies. He has over 1,150 publications in the fields of Vitamin D, calcitonin, parathyroid hormone and vitamin A and over 205 active US patents plus over 722 foreign filings corresponding to the US patents.
Dr. DeLuca has devoted his research career mainly to vitamin D and physiological events linked to the function of this vitamin. His major initial discoveries were the identification of the vitamin D active forms, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3, and the characterization of the enzymes involved in the vitamin D metabolic pathways. His group essentially defined the vitamin D-based endocrine system.
Julien Meissonnier has 13 years of experience in pharmaceutical development and leads Catalent’s European Center of Excellence for the development of lipid-based drug delivery solutions. He provides technical and scientific leadership for the development of poorly soluble drugs that lead to approvable regulatory dossiers.
Mr. Meissonnier received his Engineer Degree in Physico-Chemistry from the ISMRa in Caen, France. He is an expert in his field and currently sits on the Board of Directors with the Alsace BioValley life sciences and healthcare cluster based in France. As a board member, he supports Alsace BioValley in its efforts to continue driving growth in the life sciences by identifying and coordinating ambitious projects that will create employment opportunities in the region.
To register for the webinar, please visit http://www.xtalks.com/events/xto445catalent/index.html
About Catalent
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs more than 8,200 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.
more products. better treatments. reliably supplied.™
Media Contact: Patricia McGee
T 1+(732) 537 6407
patricia.mcgee@catalent.com
